<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921856</url>
  </required_header>
  <id_info>
    <org_study_id>ACOVA-1</org_study_id>
    <nct_id>NCT00921856</nct_id>
  </id_info>
  <brief_title>Abnormal Coronary Vasomotion in Patients With Suspected Coronary Artery Disease (CAD)</brief_title>
  <acronym>ACOVA</acronym>
  <official_title>Abnormal Coronary Vasomotion in Patients With Suspected CAD But Normal Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Ong, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Robert Bosch Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with chest pain and/or shortness of breath coronary artery disease (CAD) is
      suspected depending on the pattern of symptoms and the electrocardiogram (ECG). Coronary
      angiography is the method of choice to verify this suspicion. If the patient coronary
      arteries on coronary angiography are totally normal, one can only speculate if the patients'
      discomfort is from the heart or not. A possibility to get further information about the
      healthiness of the coronary arteries is the acetylcholine test (ACH-test). When injecting
      this natural, body produced-substance into the coronary arteries one can test if the vessels
      coronary spasm which can be the reason for the patient's symptoms. The investigators
      therefore use this test in this study to look for coronary spasm in patients with suspected
      CAD but normal coronary arteries. In case of a positive test, the patient profits from having
      found a cause for his/her symptoms making treatment with special tablets possible.
      Furthermore, the investigators want to analyze blood samples of every patient to look for
      signs of inflammation that seem to be linked with coronary spasms. On the basis of these
      results the ACH-test could probably be avoided in the future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality (cardiac vs. non-cardiac)</measure>
    <time_frame>12-36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angina pectoris, repeated angiography, re-admissions for angina pectoris</measure>
    <time_frame>12-36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Coronary Vasospasm</condition>
  <condition>Microvascular Angina</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CAD</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients admitted with suspicion of CAD and proof of CAD after coronary angiography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-CAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients admitted with suspicion of CAD but without proof of CAD after coronary angiography will undergo intracoronary acetylcholine provocation test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intracoronary acetylcholine provocation test</intervention_name>
    <description>Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.</description>
    <arm_group_label>No-CAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between 35 and 95 years old with angina pectoris and/or dyspnea suggestive of
             coronary artery disease with non-invasive proof of coronary ischemia or high pre-test
             probability for CAD who will be referred for coronary angiography

          -  Serum creatinine &lt; 1,4 md/dl

          -  Left ventricular ejection fraction &gt; 50%

        Exclusion Criteria:

          -  Patients under 35 years and above 95 years of age

          -  Severe chronic obstructive pulmonary disease (contraindication for
             acetylcholine-testing)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Ong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert Bosch Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anastasios Athanasiadis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert Bosch Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Udo Sechtem, MD</last_name>
    <role>Study Director</role>
    <affiliation>Robert Bosch Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Ong, MD</last_name>
    <phone>+4971181015449</phone>
    <email>petereong@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anastasios Athanasiadis, MD</last_name>
    <phone>+4971181015444</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Robert Bosch Medical Center</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Ong, MD</last_name>
      <phone>+4971181016048</phone>
      <email>petereong@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anastasios Athanasiadis, MD</last_name>
      <phone>+4971181015444</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Robert Bosch Medical Center</investigator_affiliation>
    <investigator_full_name>Peter Ong, MD</investigator_full_name>
    <investigator_title>Oberarzt</investigator_title>
  </responsible_party>
  <keyword>Acetylcholine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Vasospasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcholine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

